The ECE1 Knockout A2780 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population derived from the A2780 ovarian carcinoma cell line, featuring targeted disruption of the ECE1 gene. This knockout model abrogates functional expression of endothelin-converting enzyme-1 (ECE1), allowing direct interrogation of ECE1-mediated processes. The polyclonal format yields a genetically diverse pool suitable for population-level studies and high-throughput applications.
A2780 is an epithelial ovarian carcinoma cell line established from an untreated endometrioid adenocarcinoma and extensively used as a platinum-sensitive model in ovarian cancer research. It maintains key signaling pathways representative of ovarian tumors and provides a reproducible platform for gene editing and comparative phenotypic analyses.
ECE1 encodes a membrane-bound metalloprotease that proteolytically activates big endothelin-1 (big ET-1) to mature endothelin-1 (ET-1). Secreted ET-1 engages G-protein coupled ETA and ETB receptors, triggering Gq/11-dependent phospholipase C (PLC) signaling. PLC-mediated generation of IP3 and DAG mobilizes intracellular calcium and activates protein kinase C (PKC), which feed into the MAPK/ERK cascade via MAPK1/3 and the PI3K-Akt pathway via AKT1. ECE1 expression is positively regulated by TNF-alpha, TGF-beta, and HIF-1alpha, integrating inflammatory and hypoxic stimuli.
In ovarian carcinoma, aberrant ECE1?CET-1 signaling promotes cell proliferation, survival, migration, and chemoresistance. The A2780 knockout model enables researchers to delineate the specific contributions of ECE1-generated ET-1 to these malignant traits by comparing knockout and parental cells, with a focus on MAPK/ERK and PI3K-Akt activity readouts.
Key applications include functional characterization of ECE1 in ovarian cancer cell behavior using proliferation (MTS) and Transwell migration/invasion assays, drug sensitivity profiling with endothelin receptor antagonists such as macitentan or bosentan, and analysis of phospho-ERK/phospho-Akt by Western blotting. Secreted ET-1 levels can be measured by ELISA, and transcriptional changes in ECE1 and EDN1 assessed by RT-qPCR. For further information, contact Ascent Research.
